Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld the lower Court’s finding on monetary damages amounting to $23.9 million at the time of the trial, November 2018, awarding Bio-Rad a 15 percent royalty on past and future sales, and a permanent injunction against 10x’s Single Cell 3’ Gene Expression products, Single Cell ATAC-seq products, and Single Cell V(D)J products that were found to infringe the ‘083 patent.
The Court of Appeals also withdrew the District Court’s injunction with respect to 10x’s Linked-Read and CNV product lines and reversed the District Court’s decision on infringement of two other patents asserted by Bio-Rad. Bio-Rad does not believe these aspects of the Court’s decision will have a material impact on the overall result and is evaluating its options for further review.
“We are pleased that the Appeals Court upheld the District Court’s finding that 10x willfully infringed Bio-Rad’s intellectual property rights and affirmed the jury’s award of damages,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make concerning our belief that the Court of Appeals also withdrawing the District Court’s injunction with respect to 10x’s Linked-Read and CNV product lines and reversing the District Court’s decision on infringement of two other patents asserted by Bio-Rad will not have a material impact on the overall result, and that we are evaluating our options for further review with respect to these aspects of the Court’s decision. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "continue", "will," "expect," "anticipate," "plan," "intend," "estimate," "believe," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to intellectual property rights, international legal and regulatory risks, our ability to develop and market new or improved products, our ability to compete effectively, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005367/en/
Contacts:
Kevin Han, Senior Director
Investor Relations
510-741-6777
ir@bio-rad.com
